Pavlo Kucher

Obtain contributions for the development of McGill institutes and schools Obtain contributions for inter-sectoral, inter-disciplinary and international partnerships Obtain contributions for a wide array of non-peer reviewed academic, research, and partnership initiatives Discussions with federal officials to improve Canada's immigration policies and procedures Discussions with federal officials to encourage the development of a public policy framework that responds to the needs of post-secondary education and research Discussions with federal officials to advocate for increased support to the base budgets of the three granting councils, the Canada Foundation for Innovation, and Genome Canada Discussions with federal officials to advocate for increased funding for the institutional costs of research Discussions with federal officials regarding campus infrastructure and deferred maintenance issues Discussions regarding science, technology and innovation policy frameworks with a view to enhancing Canada's research and innovation capacity Discussions aimed at putting the framework in place to make Canada a top destination for work and study by the best and brightest around the world Communications with federal officials to advocate for increased federal investment in scholarships for graduate students

To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda. To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada. To actively promote the enhancement of publicly funded women’s health initiatives/programs. Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.